Published in Cancer Weekly, February 1st, 2000
"Immune therapy of malignant tumors could be achieved by the destruction of the tumor vasculature," reported J. M. Ramage and colleagues from the Nottingham University and City Hospital, United Kingdom. "Our aim is to design a vaccine that results in the generation of T cells against tumor endothelial specific antigens."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.